Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs

Description: GBI Research, the leading business intelligence provider, has released its latest research "Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs". The report provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in the US with key data, information and analysis of pricing and reimbursement decisions across the US. The report closely scrutinizes major changes in pharmaceuticals-related pricing and reimbursement in the US in the recent past and the impact these changes will have in the future. It also describes the efforts taken by the US government and private sector in shaping the pricing and reimbursement policies of brand name and generic drugs. The pricing and reimbursement scenario in some of the major therapy areas of the US has been described with the help of informative case studies.

GBI Research has found that expenditures towards healthcare have increased in the US which has led to an increased life expectancy among the Americans. When compared to the top five countries of Europe (France, Germany, the UK, Italy and Spain), the US has the highest per capita expenditures on healthcare. Out-of-pocket spending is minimal in the US, due to a strong reimbursement system provided by the public and private sector, that covers most age groups and communities. A majority of the US population is under insurance coverage, with private health insurance having a larger share than government health insurance. Most of the states have developed their own insurance plans for the benefit of their residents.

With an increase in the working class and ageing population, chronic diseases, age-related diseases and diseases due to sedentary lifestyle are expected to rise in the future indicating increasing healthcare expenditures. The US President has been implementing a number of changes in the reimbursement system in order to reduce national deficits. The Patient Protection and Affordable Care Act (PPACA) has been introduced to take care of the deficits. The US budget has been designed to reduce deficits and bring about major reforms in the healthcare system of the US.

Scope

- Detailed study of the healthcare systems in the US.
- Political, economical, social and technological analysis of the US pharmaceutical industry.
- Analysis of the pricing and reimbursement mechanisms in the US.
- Key trends that follow from the recent changes brought about in the pricing and reimbursement system.
- Build an understanding of the possible major challenges that may arise due to the changes in the pricing and reimbursement scene in the US.
- Insight into various reimbursement programs in the US with case studies.
- Particular focus on the pricing and reimbursement in major therapy areas with case studies.

Reasons to buy

- Build an understanding of the pharmaceuticals-related key pricing and reimbursement mechanisms in the US.
- Optimize your investment through identification and understanding of the changes in the pharmaceuticals regulatory mechanism in the US.
- Develop effective business strategies related to new drug launches through the analytical insight gained
from key trends in the pricing and reimbursement scene of the US.

- Improve negotiations with the government agencies to maximize reimbursement of drugs by understanding the mechanisms involved.

Contents:

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Pricing and Reimbursement in the US - Introduction
2.1 GBI Research Report Guidance

3 Healthcare System in the US - Overview
3.1 Healthcare Expenditure
3.1.1 Healthcare Expenditure and GDP
3.1.2 Healthcare Expenditure by Category
3.2 Healthcare Infrastructure
3.2.1 Hospitals
3.2.2 Hospital Beds
3.2.3 Healthcare Professionals
3.3 Health Insurance
3.3.1 Health Insurance Coverage
3.3.2 Health Insurance Providers
3.4 Demographic Trends Affecting Healthcare
3.4.1 Population Demography

4 Pharmaceutical Regulations in the US - Overview
4.1 Pharmaceutical Industry in the US
4.1.1 PEST Analysis
4.2 Healthcare Regulation
4.2.1 Highlights of the Budget 2011-2012

5 Pricing of Pharmaceutical Drugs in the US
5.1 Pricing Overview
5.1.1 Regulatory Bodies
5.1.2 Pricing Control
5.1.3 340B Drug Pricing Program
5.2 Key Trends
5.2.1 Brand Name Drug Prices Increase in the Face of Generic Competition
5.2.2 Significant Decrease in Average Price of Generic Drugs
5.2.3 PPACA Introduced by the US President to Tackle Soaring Prescription Drug Prices
5.2.4 Generic Price War at Retail Sector
5.3 Major Challenges
5.3.1 Reducing Wastage in Healthcare Spending
5.3.2 Government’s Cost Rationalization Efforts will make Future Tough for Big Pharmaceutical Companies
5.3.3 Medicaid Pricing for Dual Eligibles of Medicare Part - D
5.3.4 New ICD-10 (International Classification of Diseases) Coding System
5.3.5 Medicare Part B Drug Pricing Does Not Reflect Market Price Accurately

6 Reimbursement of Pharmaceutical Drugs in the US
6.1 Regulatory Bodies
6.2 Prescription Drugs
6.3 Biologics
6.4 Preferred Drug List (PDL)
6.5 Reimbursement by Health Insurance Companies
6.5.1 UnitedHealth Group
6.5.2 WellPoint, Inc.
6.5.3 Kaiser Foundation Group
6.5.4 Humana Group
6.5.5 Aetna Group
6.6 Pharmacy Benefit Managers (PBMs)
6.7 Reimbursement Programs in the US
6.7.1 Case Studies
6.8 Key Trends
6.8.1 Rebate Reforms and Healthcare Cuts to Reduce Federal Deficit
6.8.2 Medicare Part D Changes in Standard Benefit Parameters
6.8.3 Reimbursement of Brand Name Drugs
6.8.4 Reimbursement of Generic Drugs
6.8.5 CMS Finalizes Medicare Hospital Outpatient Payment Rates for 2012

6.9 Major Challenges
6.9.1 New Nationwide Database to Set Healthcare Reimbursement Rates
6.9.2 First DataBank/Medi-Span Settlement and the Impact on AWP
6.9.3 Renewal of Medicaid Drug Payment Policy
6.9.4 Proposed Cuts in Medicare Part B Reimbursement
6.9.5 New Trend in Free Trade Agreements Could Affect Healthcare Programs

7 Pricing and Reimbursement in the US - Major Therapy Areas
7.1 Pricing and Reimbursement in Major Therapy Areas
7.1.1 Heart Diseases
7.1.2 Cancer
7.1.3 Respiratory Diseases
7.1.4 Cerebrovascular Diseases
7.1.5 Other Major Therapy Areas
7.2 Case Studies
7.2.1 Provenge under Medicare Coverage
7.2.2 AstraZeneca Ensures Reimbursement of Brilinta
7.2.3 Financial Assistance for Orphan Drug Letairis
7.2.4 Coverage for Biologic Product Enbrel

8 Pricing and Reimbursement in the US - Appendix
8.1 Market Definitions
8.2 Abbreviations
8.3 Research Methodology
8.3.1 Healthcare System
8.3.2 Pharmaceutical Regulations
8.3.3 Pricing of Pharmaceutical Drugs
8.3.4 Reimbursement of Pharmaceutical Drugs
8.3.5 Pricing and Reimbursement in Major Therapy Areas
8.4 Contact Us
8.5 Disclaimer
8.6 Sources

1.1 List of Tables
Table 1: Pricing and Reimbursement in the US, Healthcare Expenditure as % of GDP versus Life Expectancy at Birth in Years, 1995-2009
Table 2: Pricing and Reimbursement in the US, Comparison of Per Capita GDP and Per Capita Total Expenditure on Health ($ PPP), 2000-2009
Table 3: Pricing and Reimbursement in the US, Per Capita Total Expenditure on Health ($ PPP), The US versus Top Five Countries of Europe, 2009
Table 4: Pricing and Reimbursement in the US, Total Expenditure on Health as % of GDP, The US versus Top Five Countries of Europe, 2009
Table 5: Pricing and Reimbursement in the US, National Healthcare Expenditure ($bn), By Category, 2009
Table 6: Pricing and Reimbursement in the US, Per Capita National Healthcare Expenditure ($ PPP), By Type, 2009
Table 7: Pricing and Reimbursement in the US, Out-of-Pocket Expenditure on Health (% of Total Healthcare Expenditure), The US versus Top Five Countries of Europe, 2009
Table 8: Pricing and Reimbursement in the US, National Healthcare Expenditure (%), Type of Sponsor, 2009
Table 9: Pricing and Reimbursement in the US, Type and Number of Hospitals, 2011
Table 10: Pricing and Reimbursement in the US, Healthcare Professionals, 2010
Table 11: Pricing and Reimbursement in the US, Health Insurance Coverage, Population (in million), 2009
Table 13: Pricing and Reimbursement in the US, Population Demography (Million), 2000-2010
Table 14: Pricing and Reimbursement in the US, Health Indicators, 2000-2010
Table 15: Pricing and Reimbursement in the US, Annual Retail Price Index Change in Brand Name Drugs and Generic Drugs (%), 2008-2010
Table 16: Pricing and Reimbursement in the US, Annual Price Index Change in Prescription Drugs (%), 2008-2010
Table 17: Pricing and Reimbursement in the US, Average Retail Coinsurance Rates (%), By Tier, 2009
Table 18: Pricing and Reimbursement in the US, Top Health Insurance Companies, Revenue ($bn), 2010
Table 19: Pricing and Reimbursement in the US, Reimbursement Programs, 2011
Table 20: Pricing and Reimbursement in the US, State Discount Programs, 2011
Table 21: Pricing and Reimbursement in the US, Medicare Part D Changes in Standard Benefit Parameters ($), 2008-2012
Table 22: Pricing and Reimbursement in the US, Brand Name Drug Cost-Sharing (%), 2011-2020
Table 23: Pricing and Reimbursement in the US, Generic Drug Cost-Sharing (%), 2011-2020
Table 24: Pricing and Reimbursement in the US, Major Therapy Areas by Mortality (%), 2009

1.2 List of Figures
Figure 1: Pricing and Reimbursement in the US, Healthcare Expenditure as % of GDP versus Life Expectancy at Birth in Years, 1995-2009
Figure 2: Pricing and Reimbursement in the US, Comparison of Per Capita GDP and Per Capita Total Expenditure on Health ($ PPP), 2000-2009
Figure 3: Pricing and Reimbursement in the US, Per Capita Total Expenditure on Health ($ PPP), The US versus Top Five Countries of Europe, 2009
Figure 4: Pricing and Reimbursement in the US, Total Expenditure on Health as % of GDP, The US versus Top Five Countries of Europe, 2009
Figure 5: Pricing and Reimbursement in the US, National Healthcare Expenditure (%), By Category, 2009
Figure 6: Pricing and Reimbursement in the US, National Healthcare Expenditure (% of Total Health Expenditure), By Type, 2009
Figure 7: Pricing and Reimbursement in the US, National Healthcare Expenditure (%), By Payer, 2009
Figure 8: Pricing and Reimbursement in the US, Out-of-Pocket Expenditure on Health (% of Total Healthcare Expenditure), The US versus Top Five Countries of Europe, 2009
Figure 9: Pricing and Reimbursement in the US, National Healthcare Expenditure (%), Type of Sponsor, 2009
Figure 10: Pricing and Reimbursement in the US, Total Hospital Beds per 1,000 patients, 2000-2009
Figure 11: Pricing and Reimbursement in the US, Health Insurance Coverage (% of Population), 2009
Figure 12: Pricing and Reimbursement in the US, Public Health Insurance Coverage (% of Population), 2009
Figure 13: Pricing and Reimbursement in the US, Private Health Insurance Coverage (% of Population), 2009
Figure 14: Pricing and Reimbursement in the US, Other Private and Government Insurance, 2011
Figure 15: Pricing and Reimbursement in the US, Public and Private Health Insurance Coverage (% of Population), 2007-2009
Figure 16: Pricing and Reimbursement in the US, Population by Age (Million), 2000-2010
Figure 17: Pricing and Reimbursement in the US, Pharmaceutical Industry, PEST Analysis, 2011
Figure 18: Pricing and Reimbursement in the US, Healthcare Regulation, Operating Divisions and their Functions, 2009
Figure 19: Pricing and Reimbursement in the US, Distribution Channel Logistics and Pricing, 2011
Figure 20: Pricing and Reimbursement in the US, Annual Retail Price Index Change in Brand Name Drugs and Generic Drugs (%), 2008-2010
Figure 21: Pricing and Reimbursement in the US, Annual Price Index Change in Prescription Drugs (%), 2008-2010
Figure 22: Pricing and Reimbursement in the US, ICD-10 Coding System; Features and Benefits
Figure 23: Pricing and Reimbursement in the US, Comparison Between Fee for Service, HMO and PPO, 2011
Figure 24: Pricing and Reimbursement in the US, Top Health Insurance Companies, Revenue ($bn), 2010
Figure 25: Pricing and Reimbursement in the US, Standard Medicare Part D Benefit, 2011-2020
Figure 26: Pricing and Reimbursement in the US, Brand Name Drug Cost-Sharing (%), 2011-2020
Figure 27: Pricing and Reimbursement in the US, Generic Drug Cost-Sharing (%), 2011-2020
Figure 28: Pricing and Reimbursement in the US, Major Therapy Areas by Mortality (%), 2009

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2021365/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name: | Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs |
| Web Address: | http://www.researchandmarkets.com/reports/2021365/ |
| Office Code: | SCD294Q9 |

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 3500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 7000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprise Wide:</td>
<td>USD 10500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Prof</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World